HR-positive/HER2-negative breast cancers are by far the most common subtype in the United States, comprising 68% of all diagnosed invasive female breast cancers, followed by HR-positive/HER2-positive and HR-negative/HER2-negative (triple negative) breast cancer, each at ten percent overall [1]. The gene discussed is ERBB2; the disease is breast cancer.